Is Apogee Therapeutics, Inc. (APGE) a Buy, Sell, or Hold?
Apogee Therapeutics, Inc.
NASDAQ:APGE
$133.96 USD
$0.14 (0.1%)
- Volume
- 1.74M
- Average Volume
- 2.56M
- Market Capitalization
- $8.26B
- P/E Ratio
- -30.94
- Dividend Yield
- 0.00%
- Price Target
- $135.00
- Year High
- $134.13
- Year Low
- $34.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $32.59
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael Thomas Henderson |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | APGE |
| CUSIP | 03770N101 |
| CIK | 0001974640 |
| Web | https://www.apogeetherapeutics.com |
| Phone | 650-394-5230 |
| Currency | USD |
| Employees | 261 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 32.59 |
| Quick Ratio | 32.59 |
| Cash Ratio | 13.71 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.38 |
| Price / Cash Flow | -35.11 |
| Price / Book | 7.43 |
Price Target and Rating
| Average Stock Price Forecast | $135.00 |
| High Stock Price Forecast | $140.00 |
| Low Stock Price Forecast | $81.00 |
| Forecast Upside/Downside | -0.77% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.22 |
| Trailing P/E Ratio | -30.94 |
| PEG Ratio | 1.68 |
| P/E Growth | 1.68 |
| Net Income | $-255.84M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -32.64% |
| Return on Assets | -21.23% |
Financials Score
| AltmanZ Score | 130.56 |
| Piotroski Score | 2.00 |
| Working Capital | 1.04B |
| Total Assets | 1.29B |
| Ebit | -274.34M |
| Market Cap | 8.26B |
| Total Liabilities | 37.86M |
Poll Results
About Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts. ...
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
2026-07-13 17:06:04
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
2026-07-06 21:00:00
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
2026-07-06 20:02:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-07-02 05:34:34
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
2026-07-02 05:34:00
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
2026-06-30 15:45:00
AbbVie knows how to plan ahead.
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
2026-06-29 12:11:05
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
2026-06-25 14:00:00
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Frequently Asked Questions
-
What is the current Apogee Therapeutics, Inc. (APGE) stock price?
-
Apogee Therapeutics, Inc.(NASDAQ:APGE) stock price is $133.96 in the last trading session. During the trading session, APGE stock reached the peak price of $134.13 while $34.34 was the lowest point it dropped to. The percentage change in APGE stock occurred in the recent session was 0.1% while the dollar amount for the price change in APGE stock was $0.14.
-
APGE's industry and sector of operation?
-
The NASDAQ listed APGE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APGE?
-
Emily Cox | Senior VP & Head of People
Jane Pritchett V. Henderson | Chief Financial Officer
Rebecca Dabora | Chief Development Officer
Noel Kurdi | Vice President of Investor Relations
Wendy Aspden-Curran | Senior Vice President of Clinical Operations -
How many employees does APGE have?
-
Number of APGE employees currently stands at 261. APGE operates from 221 Crescent Street, Waltham, MA 02453, US.
-
Link for APGE official website?
-
Official Website of APGE is: https://www.apogeetherapeutics.com
-
How do I contact APGE?
-
APGE could be contacted at phone #650-394-5230 and can also be accessed through its website. APGE operates from 221 Crescent Street, Waltham, MA 02453, US.
-
How many shares of APGE are traded daily?
-
The average number of APGE shares traded daily for last 3 months was 2.56M.
-
What is the market cap of APGE currently?
-
The market value of APGE currently stands at $8.26B with its latest stock price at $133.96